November 28, 2021

Medical Trend

Medical News and Medical Resources

Fujifilm uses PNI technology to make nanoparticles for VLP COVID-19 vaccine

Fujifilm uses PNI technology to make nanoparticles for VLP COVID-19 vaccine

Fujifilm uses PNI technology to make nanoparticles for VLP COVID-19 vaccine



 

Fujifilm uses PNI technology to make nanoparticles for VLP COVID-19 vaccine.

VLP Therapeutics hired Fujifilm to help it manufacture COVID-19 vaccine candidates for clinical trials. According to the undisclosed financial terms of the transaction, Fujifilm needs to produce lipid nanoparticles for delivery of mRNA vaccines, and will participate in the process and formulation development, with the purpose of working hard to advance the vaccine to the clinical trial stage.

 

Mizuki Itou, a spokesperson for Fujifilm Holdings (the parent company of Fujifilm), told us: “This collaboration is under the responsibility of Fujifilm’s pharmaceutical department in Japan,” Itou explained, “We will use the PNI NanoAssembler series of technologies to make nanoparticles. , Production will be carried out at the facilities of Fujifilm Toyama Chemical Company in Toyama Prefecture, Japan.”

 

As early as March last year, Fujifilm partnered with Canada-based Precision Nano Systems (PNI) to reach an agreement focusing on adding nano-drug development and production capabilities to its products, thereby obtaining this technology.

 

Itou added, “Fujifilm Diosynth Biotechnology, our contract development and manufacturing organization (CDMO), did not participate in the project.”

 

VLP’s COVID-19 vaccine candidate is based on self-replicating RNA vector technology. The idea is to provide genes that can change the characteristics of macrophages or dendritic cells so that they can activate the immune system to destroy cancer cells.

 

Facts have proved that the vaccine induces virus-neutralizing antibodies within two weeks after vaccination. According to a report by NS-Healthcare, the VLP plans to conduct further animal research and clinical trials in Japan with the National Center for Global Health and Medical Sciences, the National Institute of Biomedical Innovation, Health and Nutrition, Oita University and Osaka City University.

 

According to an agreement negotiated in August 2020, the vaccine development project is also supported by the Japan Medical Research and Development Agency (AMED).

The commercial scale production plan of the vaccine is underway.

 

Itou told us: “So far, no decision has been made on commercial supply. As the project progresses, we will discuss with VLP Therapeutics.”

 

About PNI

In June of this year, Danaher’s life science platform completed the acquisition of Precision NanoSystems (PNI). Headquartered in Vancouver, Canada, PNI is a global expert in the development of technologies and solutions for genetic medicine (including mRNA vaccines and therapeutic drugs).

PNI will join Danaher’s life science platform and complement its current businesses (including Cytiva and Pall).

 

About Cytiva

Cytiva is a pioneer in the field of global life sciences, with 8,000 employees in more than 40 countries and regions around the world, committed to advancing unseen technologies and accelerating extraordinary treatments.

As a reliable partner for customers, Cytiva focuses on research in life sciences and biotechnology for the development of innovative vaccines, biopharmaceuticals, and new cell and gene therapies.

By improving the speed, efficiency and capabilities of drug development and biotechnology, the development and production of transformative drugs and therapies for the benefit of patients around the world. Please visit cytiva.com.cn for more information.

 

—END—

 

Fujifilm uses PNI technology to make nanoparticles for VLP’s COVID-19 vaccine

(source:internet, reference only)


Disclaimer of medicaltrend.org